Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
Angela DeMichele(University of Pennsylvania), Lewis A. Chodosh(University of Pennsylvania), Igor Makhlin(Translational Therapeutics (United States)), Brooke Goodspeed(Translational Therapeutics (United States)), Adetutu T. Egunsola(Translational Therapeutics (United States)), Killian Rohn(Translational Therapeutics (United States)), Michael D. Feldman(University of Pennsylvania), Tien-Chi Pan(Translational Therapeutics (United States)), Elizabeth M. Chislock(Translational Therapeutics (United States)), Shannon Deluca(Translational Therapeutics (United States)), Heather L. Martin(Translational Therapeutics (United States)), Jessica Savage(Translational Therapeutics (United States)), Natalie Shih(Translational Therapeutics (United States)), Christopher J. Sterner(Translational Therapeutics (United States)), Amy S. Clark(Abramson Center for Jewish Life), George K. Belka(Translational Therapeutics (United States)), Emily Shea(Translational Therapeutics (United States)), Anupma Nayak(University of Pennsylvania), Isoris Nivar(University of Pennsylvania), Samantha Dwyer(University of Pennsylvania), Yan Chen(Shanghai Jiao Tong University), Jianping Wang(Translational Therapeutics (United States)), Lindsay R. Berry(Berry & Associates (United States)), Don Berry(Berry & Associates (United States)), Lauren J. Bayne(Translational Therapeutics (United States)), Paul Wileyto(University of Pennsylvania), Jewell Graves(Translational Therapeutics (United States)), Nathan Mears(Translational Therapeutics (United States)), Dhruv K. Pant(Translational Therapeutics (United States))
Cited by 24
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
|Bristol Research (University of Bristol)|2021|589